Ryan D Kilpatrick

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Longitudinal associations between dietary protein intake and survival in hemodialysis patients
    Christian S Shinaberger
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Am J Kidney Dis 48:37-49. 2006
  2. pmc Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
  3. pmc Relationship between epoetin alfa dose and mortality: findings from a marginal structural model
    Ouhong Wang
    Department of Global Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, California 91320, USA
    Clin J Am Soc Nephrol 5:182-8. 2010
  4. doi Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions
    Ryan D Kilpatrick
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 22:111-21. 2013
  5. doi The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study
    Ryan D Kilpatrick
    Amgen, Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 20:914-21. 2011
  6. doi Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousands Oaks, CA 91320, USA
    Am J Kidney Dis 54:554-60. 2009
  7. doi Confounding and control of confounding in nonexperimental studies of medications in patients with CKD
    Brian D Bradbury
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Adv Chronic Kidney Dis 19:19-26. 2012
  8. doi Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients
    Ryan D Kilpatrick
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA
    Am J Nephrol 37:389-98. 2013
  9. pmc CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis
    Geoffrey A Block
    Denver Nephrologists PC, Denver, Colorado, Center for Observational Research, Amgen, Inc, Seattle, Washington, Outcomes Insights, Inc, Westlake Village, California
    Clin J Am Soc Nephrol 8:2132-40. 2013
  10. ncbi Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients
    Deborah L Regidor
    Division of Nephrology and Hypertension, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509 2910, USA
    J Am Soc Nephrol 17:1181-91. 2006

Detail Information

Publications19

  1. ncbi Longitudinal associations between dietary protein intake and survival in hemodialysis patients
    Christian S Shinaberger
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Am J Kidney Dis 48:37-49. 2006
    ..We hypothesized that longitudinal changes in dietary protein intake have independent associations with survival in MHD patients...
  2. pmc Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  3. pmc Relationship between epoetin alfa dose and mortality: findings from a marginal structural model
    Ouhong Wang
    Department of Global Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, California 91320, USA
    Clin J Am Soc Nephrol 5:182-8. 2010
    ..The relationship between EPO dose and 1-year mortality, adjusting for the effects of time-dependent CBI, was examined using a marginal structural model...
  4. doi Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions
    Ryan D Kilpatrick
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 22:111-21. 2013
    ..We sought to explore these assumptions empirically in the context of epoetin-alfa (EPO) dosing and mortality...
  5. doi The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study
    Ryan D Kilpatrick
    Amgen, Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 20:914-21. 2011
    ..Vitamin D sterols have been shown to increase the risk of hypercalcemia and hyperphosphatemia in clinical trials. We sought to explore these risks in real-world clinical practice...
  6. doi Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousands Oaks, CA 91320, USA
    Am J Kidney Dis 54:554-60. 2009
    ..Here, we describe sources of bias in nonexperimental studies of ESA therapy in hemodialysis patients and critically appraise analytical methods that may help minimize bias in such studies...
  7. doi Confounding and control of confounding in nonexperimental studies of medications in patients with CKD
    Brian D Bradbury
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Adv Chronic Kidney Dis 19:19-26. 2012
    ..The availability and expanded use of large health care databases have ensured greater precision and have now placed the focus on validity. Addressing the major threats to validity, such as confounding, should be a first-order concern...
  8. doi Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients
    Ryan D Kilpatrick
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA
    Am J Nephrol 37:389-98. 2013
    ..Data describing real-world use and effectiveness of cinacalcet are limited. We aimed to characterize predictors of treatment and changes in secondary hyperparathyroidism (SHPT) biochemistry after cinacalcet initiation...
  9. pmc CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis
    Geoffrey A Block
    Denver Nephrologists PC, Denver, Colorado, Center for Observational Research, Amgen, Inc, Seattle, Washington, Outcomes Insights, Inc, Westlake Village, California
    Clin J Am Soc Nephrol 8:2132-40. 2013
    ..Because these parameters may be on the same causal pathway and have been proposed as quality measures, an integrated approach to estimating event risks is needed...
  10. ncbi Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients
    Deborah L Regidor
    Division of Nephrology and Hypertension, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509 2910, USA
    J Am Soc Nephrol 17:1181-91. 2006
    ..Falling hemoglobin and requiring higher ESA doses were associated with decreased survival. Randomized clinical trials are required to examine these associations...
  11. ncbi Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute, Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Am J Kidney Dis 46:489-500. 2005
    ..However, the association between changes in weight over time and prospective mortality is not known...
  12. ncbi Hepatitis C virus and death risk in hemodialysis patients
    Kamyar Kalantar-Zadeh
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    J Am Soc Nephrol 18:1584-93. 2007
    ..More diligent efforts to prevent and treat HCV infection may improve outcomes in MHD patients...
  13. ncbi Association between serum lipids and survival in hemodialysis patients and impact of race
    Ryan D Kilpatrick
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, CA 90509 2910, USA
    J Am Soc Nephrol 18:293-303. 2007
    ..Although these associations may not be causal, they call into question whether specific subgroups of dialysis patients are better targets for cholesterol-lowering therapy...
  14. ncbi A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomiedical Research Institute, Los Angeles, California 90509 2910, USA
    Hemodial Int 9:314-24. 2005
    ....
  15. ncbi Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509 2910, USA
    Nephrol Dial Transplant 20:1880-8. 2005
    ..However, serum albumin may change over time. Hence, its time-varying associations with outcome may be different...
  16. ncbi Reverse epidemiology of blood pressure in dialysis patients
    Kamyar Kalantar-Zadeh
    Kidney Int 67:2067; author reply 2067-8. 2005
  17. ncbi Survival advantages of obesity in dialysis patients
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Am J Clin Nutr 81:543-54. 2005
    ..Weight-gaining interventional studies in dialysis patients are urgently needed to ascertain whether they can improve survival and quality of life...
  18. ncbi Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, Calif 90509 2910, USA
    Hypertension 45:811-7. 2005
    ..Although these associations may not be causal, they call into question whether treatment goals for the general population can be applied to dialysis patients or other similar populations...
  19. ncbi Reverse epidemiology: a spurious hypothesis or a hardcore reality?
    Kamyar Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, UCLA David Geffen School of Medicine, Torrance, CA 90509 2910, USA
    Blood Purif 23:57-63. 2005
    ....